Press release
Hemophilia A Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | AbbVie, Bayer, Belief Biomed, Biocad, Genzyme, Gritgen Therapeutics, Novo Nordisk, Pfizer, Poseida, Spark Therapeutics, Takeda, and TiumBioCo
"Hemophilia A Pipeline Insight" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hemophilia A Therapeutics Market.
The report provides a detailed description of the Hemophilia A drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Hemophilia A Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/hemophilia-a-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Hemophilia A Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Hemophilia A therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia A treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Hemophilia A drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Hemophilia A treatment market.
Learn More about the Clinical and Commercial Development Activities in the Hemophilia A Therapeutics Domain @
https://www.delveinsight.com/report-store/hemophilia-a-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Hemophilia A Therapeutics Analysis
Around 25+ prominent companies are actively involved in the development of therapies for Hemophilia A. Among these, Sanofi stands out for advancing its Hemophilia A drug candidates to the most advanced stage of clinical trials, specifically Phase III. This phase signifies a critical juncture in the drug development process, where the efficacy and safety of the treatment are extensively evaluated in a larger patient population. Sanofi's progress to Phase III underscores the potential significance of their therapeutic approach in addressing the challenges posed by Hemophilia A, reflecting the commitment and advancements within the field of hematology and rare diseases.
Hemophilia A Companies in the Therapeutics Market Include:
• TiumBioCo.
• JiangsuGensciencesInc.
• Pfizer
• Novo Nordisk
• Genzyme
• AbbVie
• Bayer
• Spark Therapeutics
• G&P Bioscience
• Gritgen Therapeutics
• Biocad
• Belief Biomed
• Chugai Pharmaceutical
• Staidson Beijing BioPharmaceuticals
• JiangsuGensciences (Note: This appears to be a duplicate entry)
• Poseida Therapeutics
• ChiaTai Tianqing Pharmaceutical Group
• Takeda
And Many Others
Emerging and Marketed Hemophilia A Therapies Covered in the Report Include:
• Fitusiran: Sanofi
• STSP-0601: Staidson Beijing BioPharmaceuticals
• TU7710: TiumBio
• Marstacimab: Pfizer
• ROCTAVIAN (valoctocogene roxaparvovec)
• OBIZUR (susoctocog alfa): Takeda
And Many More
Get an in-depth Assessment of the Emerging Therapies and Hemophilia A Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Hemophilia A Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Route of Administration
Hemophilia A pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Request for Sample PDF to Understand More About the Hemophilia A Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Hemophilia A Current Treatment Patterns
4. Hemophilia A - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hemophilia A Late-Stage Products (Phase-III)
7. Hemophilia A Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hemophilia A Discontinued Products
13. Hemophilia A Product Profiles
14. Hemophilia A Companies
15. Hemophilia A Drugs
16. Dormant and Discontinued Products
17. Hemophilia A Unmet Needs
18. Hemophilia A Future Perspectives
19. Hemophilia A Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hemophilia A Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | AbbVie, Bayer, Belief Biomed, Biocad, Genzyme, Gritgen Therapeutics, Novo Nordisk, Pfizer, Poseida, Spark Therapeutics, Takeda, and TiumBioCo here
News-ID: 3399287 • Views: …
More Releases from DelveInsight Business Research LLP
Alpha-1 Protease Inhibitor Deficiency Market Size 2032: CSL Behring, Grifols The …
DelveInsight's "Alpha-1 Protease Inhibitor Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Alpha-1 Protease Inhibitor Deficiency, historical and forecasted epidemiology as well as the Alpha-1 Protease Inhibitor Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Alpha-1 Protease Inhibitor Deficiency Market Research Report
• The increase in Alpha-1 Protease Inhibitor Deficiency Market Size…
Amyloidosis Market Size Report 2032: Attralus Inc., Novotech Pty Limited, Criter …
DelveInsight's "Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Amyloidosis, historical and forecasted epidemiology as well as the Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Amyloidosis Market Research Report
• The increase in Amyloidosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies…
Basal Cell Nevus Syndrome Market Size Report 2032: Latest FDA Approvals, Emergin …
DelveInsight's "Basal Cell Nevus Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Nevus Syndrome, historical and forecasted epidemiology as well as the Basal Cell Nevus Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Basal Cell Nevus Syndrome Market Research Report
• The increase in Basal Cell Nevus Syndrome Market Size…
Biliary Atresia Market Size Report 2032: Latest FDA Approvlas and Pipeline Repor …
DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Key Takeaways from the Biliary Atresia Market Research Report
• The increase in Biliary Atresia Market Size is a direct consequence of the increasing…
More Releases for Hemophilia
Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand…
Hemophilia Therapeutics Pipeline Analysis Overview
The study analysed that the hemophilia pipeline comprises of 53 drug candidates in different stages of development.
The pipeline analysis based on route of administration of active drug candidates showed, that around most of the hemophilia drug candidates are being developed to be administered by intravenous route.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis
Most of the pharma and biotech companies are developing the therapeutics for hemophilia in collaboration with educational institutes. In…
Hemophilia B - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Hemophilia B - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H1 2017, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.
Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include…
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports.
Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged…
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504
The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes…
Hemophilia Treatment Drugs Market Report 2024
Global Hemophilia Treatment Drugs Market: Overview
The global hemophilia treatment drugs market is presently catering to various sub-types of hemophilia such as hemophilia A, hemophilia B and others such as acquired hemophilia and hemophilia C. The increasing awareness of this disorder and the introduction of innovative ways of managing this disease has opened up several opportunities for the global market in recent years. According to the research report, the global hemophilia…
